|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
Biomarker |
BEFREE |
Our study indicated that serum FEZF1-AS1 and AFAP1-AS1 had better sensitivity and efficiency for the diagnosis of GC and the combination of the two lncRNAs might be used as a potential prognostic indicator in GC.
|
31785996 |
2020 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
AlteredExpression |
BEFREE |
In addition, the patients with GC with increased AFAP1-AS1 expression exhibited an advanced clinical stage and an association with the occurrence of lymph node metastasis compared with those with decreased AFAP1-AS1 expression.
|
31452798 |
2019 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
AlteredExpression |
BEFREE |
Long non-coding RNA AFAP1-AS1 is an important tumor-associated lncRNA and its aberrant expression has been found in many malignancies so far, including pancreatic ductal adenocarcinoma, cholangiocarcinoma, gallbladder cancer, hepatocellular carcinoma, gastric cancer, colorectal cancer, esophageal cancer, nasopharyngeal carcinoma, lung cancer, ovarian cancer, breast cancer, retinoblastoma, laryngeal cancer, tongue squamous cell carcinoma and thyroid cancer.
|
30173945 |
2018 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
Biomarker |
BEFREE |
This study aimed to conduct a meta-analysis on 19 lncRNAs (AFAP1 antisense RNA 1 [AFAP1-AS1], CDKN2B antisense RNA 1 [ANRIL], cancer susceptibility 15 [CASC15], colon cancer associated transcript 2 [CCAT2], gastric adenocarcinoma associated, positive CD44 regulator, long intergenic noncoding RNA [GAPLINC], H19, imprinted maternally expressed transcript [H19], HOX transcript antisense RNA [HOTAIR], HOXA distal transcript antisense RNA [HOTTIP], long intergenic non-protein coding RNA 673 [LINC00673], metastasis-associated lung adenocarcinoma transcript 1 [MALAT1], maternally expressed 3 [MEG3], promoter of CDKN1A antisense DNA damage activated RNA [PANDAR], Pvt1 oncogene [PVT1], SOX2 overlapping transcript [Sox2ot], SPRY4 intronic transcript 1 [SPRY4-IT1], urothelial cancer associated 1 [UCA1], X inactive specific transcript [XIST], ZEB1 antisense RNA 1 [ZEB1-AS1] and ZNFX1 antisense RNA 1 [ZFAS1]) to systematically estimate their prognostic value in GC.
|
30147339 |
2018 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
PosttranslationalModification |
BEFREE |
In the present study, the expression of AFAP1-AS1 in GC tissues and cell lines was measured using reverse transcription-quantitative polymerase chain reaction (RT-qPCR).
|
29805596 |
2018 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
AlteredExpression |
BEFREE |
By performing multivariate Cox regression test, AFAP1-AS1 expression level was confirmed to be an independent factor for poor prognosis in patients with GC.
|
29740481 |
2018 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
AlteredExpression |
BEFREE |
Quantitative reverse transcription-polymerase chain reaction (QRT-PCR) assay was used to evaluate the expression of lncRNA AFAP1-AS1 in GC tissues, when compared with adjacent noncancerous tissues, respectively.
|
28975981 |
2017 |
|
AFAP1-AS1
|
Stomach Carcinoma
|
0.080 |
AlteredExpression |
BEFREE |
AFAP1-AS1 was up-regulated in GC tissues and GC cells.
|
28451917 |
2017 |